`
`
`UNITED STATES DEPARTMENT OF COIVDIER("E
`United States Patent and Trademark Offict:
`Address: COMMISSIONER FOR PATENTS
`I’ O Box I450
`/\lexandria, Virginia 323134450
`www uspto gov
`
`NOTICE OF ALLOWANCE AND FEE(S) DUE
`
`02/11/2014
`
`_
`7590
`277 /7
`PHILIP S. JOHNSON
`JOHNSON & JOHNSON
`ONE JOHNSON & JOHNSON PLAZA
`NEW BRUNSWICK, NJ 08933-7003
`
`APPLlL"A'l'lOl\' NO.
`
`I-"ILIl\'(i Dz—\TIZ
`
`FIRST NAMED I,\IVIiNTt')R
`
`
`
`Alzm ll. Auerbach
`O2/Z4/2011
`I3/034,340
`TITLE OF INVENTION: METHODS AND C‘OMPOSl'l'IONS FOR TRI9.’/\'l'lN(‘r (‘ANCIYR
`
`EXAMINER
`
`nU1.s+w MING R
`
`
`
`mt
`DATE MAILED: 02/l l/Z014
`
`
`
`ATTORNI-LY DOC NO,
`("()NFIRIVIA'I l0l\' NO.
`
`
`CURSOOI l.'S(‘,\'Tl
`I597
`
`APPLN. TYPE
`ENTITY STATUS
`ISSUE
`DUE
`PUBl.l( '/\TlON
`DITE
`PREV’. PAID ISSUIZ FEE
`'l U'l'Al_ l-'l’:'lLt[SI DIII1
`DATl'3 DUI?
`
`nonprovisional
`UNDISCOUNTED
`$960
`$0
`$0
`$900
`05/12/2014
`
`TIIE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT.
`PROSECUTIQ IN ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS.
`THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON
`PETITION BY TIIE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.
`
`THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE
`MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED.
`THIS
`TAT
`Y P 4R
`T
`t
`4
`4
`t
`.
`SEE 35 U.S.C. 151. TIIE ISSUE FEE DUE INDICATED ABOVE DOES
`NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION.
`IF AN ISSUE FEE HAS
`PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SIIOWN ABOVE), THE RETURN OF PART B OF THIS FORM
`WILL BE CONSIDERED A REQUEST TO REAPPLY TIIE PREVIOUSLY PAID ISSUE FEE TOWARD TIIE ISSUE FEE NOW
`DUE.
`
`HOW TO REPLY TO THIS NOTICE:
`
`1. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that
`entity status still applies.
`If the HN'l'l'l'Y S'l‘A'l'US is the same as shown above, pay the 'l‘O'l‘Al. FHH(S) DUH shown above,
`If the ENTITY STATUS is changed from that shown above, on PART B ~ FEE(S) TRANSMITTAL, complete section number 5 titled
`"Change in Entity Status (from status indicated above)".
`
`For purposes of this notice, small entity fees are 1/2 the amount of uudiseonnted fees, and micro entity fees are 1/2 the amount of small entity
`fees.
`
`ll. PART B - I’l3E(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Oflice
`(USPTO) with your ISSUE FEE and PUBLICATION
`(if required). If you are charging the l‘ee(s) to your deposit account, section "4b"
`of Part B - Fee(s) Transmittal should be completed and an extra copy of the lionn should be submitted. If an equivalent of Paul B is filed, a
`request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recogni7,ing
`the paper as an equivalent of Part B.
`
`III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to
`Mail Stop ISSUE
`unless advised to the contrary.
`
`IMPORTANT REMINDER: Utility patents issuing on applications tiled on or after Dec. 12, 1980 may require payment of
`maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.
`
`PTOL-85 (Rev. 02/11)
`
`Page I of 3
`
`JANSSEN EXHIBIT 2165
`
`Wockhardt v. Janssen lPR2016-01582
`
`JANSSEN EXHIBIT 2165
`Wockhardt v. Janssen IPR2016-01582
`
`

`

`PART B - FEE(S) TRANSMITTAL
`
`Complete and send this form, together with applicable fee(s), to: _Mg;i_l_ Mail Stop ISSUE FEE
`Commissioner for Patents
`PO. Box 1450
`Alexandria, Virginia 22313-1450
`(571)-273-2885
`
`
`
`
`
`through 5 should be completed where
`INSTRUCTIONS: This form should be used for transmitting the ISSUE F'F.E and I’I‘BI.lCATION FEE (ifrequired). Blocks 1
`‘ctp ropriate. All furthei' correspondence including the Patent, advance orders and notification of maintenance lees will be mziiled to the current t'tiri‘esfl3ndence address as
`inclaicated unless corrected below or directed otherwise in Block 1, by (a) specifying :1 new coirespondence address: and/or (I3) indicating a separate ‘
`‘
`~
`Li ADDRESS" for
`maintenance fee notifications.
`
`or _I;a_ig
`
`CURRENT CORRESPONDENCE ADDRESS (Note: Use B1-Wk 1 M an)’ Change oiadctrcssi
`
`7590
`27777
`g
`PI HLIP S. JOHNSON
`JOHNSON & JOHNSON
`ONE JOIINSON & JOHNSON PLAZA
`NEW BRUNSWICK, NJ 08933-7003
`
`02/1 1/2014
`
`can only be used for domestic mailings of the
`Note: A certificate of mailin
`Fee(s) Transmittal. This cei‘tiiicnte cannot be used for any other ucconipanying
`apers. Each additional paper. such as an assignment or formal drawing. must
`ave its own eei'tit'icale of mailing or transmission.
`
`Certificate 01' Mailing or Transmission
`I hereb certify that this l"ee(s) Trzinsrnittal is being deposited with the Iinited
`States ostal Service with sufficient postage for first class mail in an envelope
`addressed to the Mail Sto
`ISSUE
`address above, or being facsimile
`transmitted to the IISPTO (. 71) 2732885, on the date indicated below.
`
`
`
`
`(Sigiiatiire)
`
`
`
`
`
`
`FIRST NAMED INVENTOR
`
`
`(’?ON'FIRMA'I'ION .\I().
`FILING DATE
`APPLICATION NO.
`I597
`Alan II. Auerbach
`O2/24/2011
`13/034,340
`CGRSOOIUSCNTI
`TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING CANCER
`
`APPLN. TYPE
`
`nonprovi siomil
`
`
`
`
`
`1iN'l'I'I'Y STATUS
`UNDISCOUNTED
`
`
`
`DUE
`
`ISSUE
`$960
`ART UNIT
`
`
`
`PUlIl..lCA'1'lON 15151;‘ DUI.’
`PRIJV. PAID ISSUE
`'I'()'1'A.L l*'I."Ii(S) DUIS
`D/\'1'1i DUI;
`
`$0
`$0
`$960
`05/12/2014
`CLASS-SUB CLASS
`
`
`
`5l4~170()()0
`HUI. SAN MING R
`1621
`1. Change of correspondence address or indication of "Fe
`
`
`
`CPR 1.363),
`Z. I-'or printing on the patent front page, list
`e Address" (37
`(I) The names of tip to 3 registered pzitent zittorneys
`l
`~
`---- -
`3 Chan e oi" correspondence address (or Change oi‘ Correspondence
`or agents OR, alternatively,
`Address orm PTO/SB/122') attached.
`(2) The name ol‘ 2! single firm (having as a member ii
`3 "Fee Address" indication (or "Fee Address" Indication form
`registered attorney or agent) and the names of tip to
`PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer
`Number is required.
`g
`.2 registered patent attorneys or agents. If no name is
`
`
` listed. no name will be printed. ' ’”""’“”"'<"""(" ”“"” “"‘“ W"
`
`3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)
`If an assignee is identified below, the document has been filed for
`PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent.
`recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.
`(A) NAME OF ASSIGNEE
`(B) RESIDENCE: (CITY and STATE OR COUNTRY)
`
`——--- N —
`
`
`
`
`
`Please check the appropriate assignee category or categories (will not be printed on the patent) 7 D individual D Corporation or other private group entity D Government
`
`
`
`4a. The following feets) are submitted:
`4b. Payment of Fee(s): (Please firs! reapply any previously paid issue fee shown above)
`3 Issue Fee
`3 A check is enclosed.
`3 Publication Fee (No small entity discount permitted)
`3 Payment by credit card. Form P'l'O~.ZO38 is attached.
`:1 Advance Order — # of Copies
`:lThc Director is hereby authorized to charge the reqiiired fee(s), any deficiency, or credits any
`overpayment, to Deposit Account Number
`(enclose an extra copy of this form).
`
`5. Change in Entity Status (from status indicated above)
`3 Applicant certifying micro entity status. See 37 CFR 129
`NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue
`fee payment in the m.iero entity amount will not be accepted at the risk of application abandonment.
`3 Applicant asserting small entity status. See 37 CFR 1.27
`NOTE: If the application was previously under micro entity status, checking this box will be taken
`to be a notification ofloss ofentitlement to micro entity status.
`3 Applicant changing to regular undiscounted fee status.
`NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro
`entity status, as applicable.
`NOTE: This form must be si ned in accordance with 37 CFR 1.31 and 1.33. See 37 CPR 1.4 for si nature re tiirements and certifications.
`
`Authorized Signature W {
`
`Date
`
`Typed or printed name
`
`R egistraiion No. (_
`
`Page 2 of 3
`
`PTOL~85 Part B (10-13) Approved for use through 10/31/2013.
`
`OMB 0651-0033
`
`U.S. Patent and Trademark Office: US. DEPAR'l'Ml.iN'l‘ Oh CO.VlMER(‘Ii
`
`

`

`
`
`APPLICATION NO.
`
`l3/034,340
`
`
`
`UNl'l‘i£D S’l‘A'l‘]:‘S PA’l‘EN'i‘ AND TRADEMARK OFFICE
`
`
`
`FILING DATE
`
`02/24/201 1
`
`
`
`l’-'IRS'l” NAMED IN V iNTOR
`
`
`
`UNITED STATES DEPARTMENT OF COMMER('7E
`United States Patent and Trademark Olfice
`Address: CIOMMISSIONER FOR PATENTS
`P O. Box I450
`Alexandria. Virginia 233134450
`www usplo gov
`
`A'l"I’ORNEY DOCKET NO.
`
`C‘()Nl7lRMATlON NO.
`
`
`
`
`
`Alan ll. Auerbach
`
`CUR5()OlUSC.\lTl
`
`1597
`
`aw. sA~ Mme K
`
`1.521
`l)A'l'l:' MAlLl:'D: 02/l l/2014
`
`PHILIP s. JOHNSON
`JOHNSON & JOHNSON
`ONF, JOHNSON & JOHNSON PLAZA
`NEW BRUNSWICK, NJ 08933-7003
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`(application filed on or after May 29, 2000)
`
`mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half
`months) after the mailing date of this notice, the Patent Term Adjustment will be 0 day(s).
`
`If a Continued Prosecution Application (CPA) was filed in the aboveidentified application,
`determines Patent Term Adjustment is the filing date of the most recent CPA.
`
`the filing date that
`
`(PAIR) WEB site (http://pair.uspto.gov).
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of
`Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be
`directed to the Customer Service Center of the Office of Patent Publication at l-(888)-786-0101 or (57 1 )«272—4200.
`
`l’TOL~85 (Rev. 02/l l)
`
`Page 3 of 3
`
`

`

`OMB Clearance and PRA Burden Statement for PTOL-85 Part B
`
`The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and
`Budget approval before requesting most types of information from the public, When OMB approves an agency
`request to collect information from the public, OMB ( i) provides a valid OMB Control Number and expiration
`date for the agency to display on the instrument that will be used to collect the information and (ii) requires the
`agency to inform the public about the OMB Control Number's legal significance in accordance with 5 Cl*‘R
`1320.5(b).
`
`The information collected by PTOL-85 Part B is required by 37 (“.l*'R 1.311. The information is required to obtain
`or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is
`governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete,
`including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary
`depending upon the individual case. Any comments on the amount of time you require to complete this form
`and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`Trademark Office, US. Department of Commerce, PO. Box 1450, Alexandria, Virginia 223134450. DO NOT
`SEND FEl£S OR COM1’l.l:5'1‘l:Ll) FORMS TO T1118 ADDRESS. SEND TO: Commissioner for Patents, PO. Box
`1450, Alexandria, Virginia 22313-1450, Under the Paperwork Reduction Act of 1995, no persons are required to
`respond to a collection of information unless it displays a valid OMB control number.
`
`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your
`submission of the attached form related to a patent application or patent. Accordingly, pursuant
`to the
`requirements of the Act, please be advised that: (1) the general authority for the collection of this information is
`35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which
`the information is used by the US. Patent and Trademark Office is to process and/or examine your submission
`related to a patent application or patent. If you do not furnish the requested information, the US. Patent and
`Trademark Office may not be able to process and/or examine your submission, which may result in termination of
`proceedings or abandonment of the application or expiration of the patent.
`
`U)
`
`The information provided by you in this form will be subject to the following routine uses:
`1. The information on this form will be treated confidentially to the extent allowed under the lireedom of
`Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records
`may be disclosed to the Department of Justice to determine whether disclosure of these records is required
`by the Freedom of Information Act.
`2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence
`to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of
`settlement negotiations.
`A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a
`request involving an individual, to whom the record pertains, when the individual has requested assistance
`from the Member with respect to the subject matter of the record.
`4, A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having
`need for the information in order to perform a contract. Recipients of information shall be required to
`comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
`5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of
`records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property
`Organization, pursuant to the Patent Cooperation Treaty.
`6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes
`of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C.
`218(0)).
`to the Administrator, General
`7. A record from this system of records may be disclosed, as a routine use,
`Services, or his/her designce, during an inspection of records conducted by GSA as part of that agency's
`responsibility to recommend improvements in records management practices and programs, under authority
`of 44 U.S.C. 29()4 and 2906. Such disclosure shall be made in accordance with the GSA regulations
`governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive.
`Such disclosure shall not be used to make determinations about individuals.
`8. A record from this system of records may be disclosed, as a routine use, to the public after either publication
`of the application pursuant to 35 U.S.C. l22(b) or issuance of a patent pursuant to 35 U.S.C. 151. Ilurther, a
`record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the
`record was filed in an application which became abandoned or in which the proceedings were terminated
`and which application is referenced by either a published application, an application open to public
`inspection or an issued patent.
`to a Federal, State, or local law
`9. A record from this system of records may be disclosed, as a routine use,
`enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.
`
`

`

`Application No.
`13/034,340
`
`App|icant(s)
`AUERBACH ET AL.
`
`fgztinit J ,’.‘.',’.:,‘:',;*‘,‘.,'.,““°“‘°"°
`gzmimra HUI
`Notice ofAllowability
`- The MAILING DATE of this communication appears on the coversheet with the correspondence address—-
`
`No
`
`|_
`
`If not included
`All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application.
`herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed In due course. THIS
`NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative
`of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.
`
`1. E This communication is responsive to 1/10/2014.
`I] A declaration(s)/affidavit(s) under 37 CFR 1.130(b) was/were filed on
`
`2. E] An election was made by the applicant in response to a restriction requirement set forth during the interview on
`requirement and election have been incorporated into this action.
`
`; the restriction
`
`3. E The allowed claim(s) is/are 37-56. As a result of the allowed c|aim(s). you may be eligible to benefit from the Patent Prosecution
`Highway program at a participating intellectual property office for the corresponding application. For more information, please see
`isttr ://www.us' to. ov/ atents/init extents/gait,/ir1dex_._j_s‘g; or send an inquiry to PPH:’eedback
`us to.<.'gov'
`.
`
`
`
`
`
`4. [:1 Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)—(d) or (1).
`Certified copies:
`
`'0) [:1 None of the:
`b) [:1 Some
`a) D All
`1. [:1 Certified copies of the priority documents have been received.
`2. El Cenified copies of the priority documents have been received in Application No.
`3. E] Copies of the certified copies of the priority documents have been received in this national stage application from the
`International Bureau (PCT Rule 17.2(a)).
`* Certified copies not received:
`
`Applicant has THREE MONTHS FROM THE “MAlLlNG DATE" of this communication to file a reply complying with the requirements
`noted below. Failure to timely comply will result in ABANDONMENT of this application.
`THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.
`
`5. [:1 CORRECTED DRAWINGS ( as “replacement sheets") must be submitted.
`
`D including changes required by the attached Examiner’s Amendment / Comment or in the Office action of
`Paper No./Mail Date
`
`Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the from (not the back) of
`each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
`6. [:1 DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the
`attached Examiner‘s comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.
`
`Attachment(s)
`1. D Notice of References Cited (PTO-892)
`2. X information Disclosure Statements (PTO/SB/O8),
`Paper No./Mail Date
`3. [:1 Examiner's Comment Regarding Requirement for Deposit
`of Biological Material
`4. 1:] Interview Summary (PTO-413),
`Paper No./Mail Date
`
`/SAN—MING HUl/
`Primary Examiner, Art Unit 1621
`
`5. E] Examiner's Amendment/Comment
`6. E Examiner's Statement of Reasons for Allowance
`
`7. C] Other
`
`U 8 Patent and Trademark Office
`
`PTOL-37 (Rev. 08-13)
`
`, Notice oi Allowabilily
`
`Part of Paper No./Mail Date 20140128
`
`
`
`

`

`Application/Control Number: 13/034,340
`Art Unit: 1621
`
`Page 2
`
`The present application is being examined under the pre—AlA first to invent
`
`provisions.
`
`DETAILED ACTION
`
`A request for continued examination under 37 CFR 1.114, including the fee set
`
`forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office
`
`action under Ex Parte Quayle, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since
`
`this application is eligible for continued examination under 37 CFR 1.114, and the fee
`
`set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has
`
`been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 1/10/2014
`
`has been entered.
`
`REASONS FOR ALLOWANCE
`
`The following is an examiner’s statement of reasons for allowance: the herein
`
`claimed method of treating prostate cancer is essentially the same as the notice of
`
`allowance mailed 7/30/2013. The commercial success of the combination of prednisone
`
`and abiraterone to treat prostate cancer obviate the rejection under 35 USC 103(a).
`
`Claims 37—56 are allowed.
`
`Any comments considered necessary by applicant must be submitted no later
`
`than the payment of the issue fee and, to avoid processing delays, should preferably
`
`accompany the issue fee. Such submissions should be clearly labeled “Comments on
`
`Statement of Reasons for Allowance.”
`
`

`

`Application/Control Number: 13/034,340
`Art Unit: 1621
`
`Page 3
`
`Any inquiry concerning this communication or earlier communications from the
`
`examiner should be directed to SAN—MING HUI whose telephone number is (571)272-
`
`0626. The examiner can normally be reached on Mon - Fri from 9:00 to 5:00.
`
`If attempts to reach the examiner by telephone are unsuccessful, the examiner’s
`
`supervisor, Melenie McCormick can be reached on (571) 272-8037. The fax phone
`
`number for the organization where this application or proceeding is assigned is 571-
`
`273-8300.
`
`Information regarding the status of an application may be obtained from the
`
`Patent Application Information Retrieval (PAIR) system. Status information for
`
`published applications may be obtained from either Private PAIR or Public PAIR.
`
`Status information for unpublished applications is available through Private PAIR only.
`
`For more information about the PAIR system, see http://pair-direct.uspto.gov. Should
`
`you have questions on access to the Private PAIR system, contact the Electronic
`
`Business Center (EBC) at 866-217-9197 (toll—free).
`
`If you would like assistance from a
`
`USPTO Customer Service Representative or access to the automated information
`
`system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
`
`/SAN-MING HUl/
`
`Primary Examiner, Art Unit 1621
`
`San-ming Hui
`Primary Examiner
`Art Unit 1621
`
`

`

`PTO/SB/08A (0800)
`Approved for use through 10/31/2002 OMB 0651-0031
`US. Patent and Trademark Office: US. DEPARTMENT OF COMMERCE
`
`
`Under the Pa rwork Reduction Acl of 1995, no ersons are reuired to resnd to a ooliection oi information unless it dis a s a valid OMB control number.
`
`Agplication Number
`Filing Date
`First Named Inventor
`G’°“A"““'‘
`Examiner Name
`Attorney Docket Number
`U.S. PATENT DOCUMENTS
`
`13/034,340
`February 24, 2011
`Alan H. Auerbach
`‘629
`San Ming R. Hui
`CGR5001USCNT1
`
`US. Patent Document
`
`Examiner
`initials
`
`Cite
`
`Kind Code
`
`(gr known)
`
`Name of patemee or Applicant
`of Cited Document
`
`Date of Publication
`of Cited Document
`mmddgyyyy
`
`Pages, Columns, Lines.
`where relevant passages or
`relevant figures appear
`
`Examiner
`‘Ways
`
`Cite
`No‘
`
`Foreign Patent Document
`___..__
`.______,____
`
`Officea Number,
`
`
`
`KindCOde5
`
`Name of Payentee or
`t
`-
`Applicantotcited Document
`
`Date of Publication
`of Cited Document
`mm-dd—
`
`WW
`
`Pages, Columns, Lines.
`where relevant
`passages or relevant
`_
`figures appear
`
`T
`
`G
`
`I.
`._i_
`
`Date
`Examiner
`
`
`Considered
`ature
`‘EXAMINER: initial it reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation it not in conformance
`and not considered. Include copy of this form with next communication to appiicant.
`
`1 Unique citation designation number. 2 See attached Kinds of US. Patent Documents. 3 Enter Office that issued the document. by the two—|etter
`code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial
`number ofthe patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if
`possible. aApp|icant is to place a check mark here it English language Translation is attached.
`
`Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs otthe individual case. Any
`comments on the amount of time you are required to complete this form should be sent to the Chief information Officer, U. S. Patent and Trademark
`Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESSSEND TO: Commissioner for Patents. PO. Box
`1450, Alexandria, VA 223131450
`
`ALL REFERENCES CONSEERED EXCEPT WHERE UNED THROUGH.
`
`/S.i-t./
`
`
`
`Substitute for f°lm1449A/PTO
`
`STATEMENT BY APPLICANT
`("Se 35 “WV 5“°°'5 as "°°95“'Yi
`Sheet 1 of 2
`
`

`

`PTO/SB/08A (0800)
`Approved for use through 10/31/2002 OMB 0651-0031
`US Patent and Trademark Office: U S, DEPARTMENT OF COMMERCE
`Under the Paiwork Reduction Act of 1995, no ersons are reuired to resnd to a collection of information unless it dis a s a valid OMB control number
`
`Substitute for form 1449A/PTO
`Agp//Cation Number
`13/034340
`F/'lingDate
`Februa_ry 24, 2011
`First Named Inventor
`Alan H. Auerbach
`8,, M.,,,_w
`CGRSOO1 U SCNTt
`
`IN
`STATEMENT BY APPLICANT
`(“S9 as "‘°"Y Sm" 8‘ ""°°5“’Vl
`Sheet 2 of 2
`
`Attorney Docket Number
`
`
`Examiner's
`Initials*
`
`Cite
`‘I No.‘ r
`
`OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
`
`include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item T“
`(book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume—issue number(s),
`publisher, city and/or country where published
`‘
`Berry, W. et al. Phase 111 Study ofMitoxantrone Plus Low Dose Prcdnisone Versus Low
`Dose Prednisonc Alone in Patients with Asymptornatic Hormone Relhictory Prostate Cancer,
`
`_r The Journal ofUro1ogy 2002_,_pages 2439-2443, Volume 168.
`
`__fl__
`
`__i
`
`r
`
`I
`
`—i
`
`T
`
`i_
`
`I
`T’
`
`T.‘
`fl
`
`‘i
`
`-‘.1
`
`_J
`
`__i
`
`Chang, Ching-Yi, ct al. Glucocorticoids Manifest Androgcnic Activity in a Cell Derived from
`a Metastatic Prostate Cancer, Cancer Research, 2001, pages 8712-8717, Volume 61.
`Dorff, TB, Crawford, ED. Management and challenges ofcorticosteroid therapy in men with
`metastatic castrate-resistant prostate cancer, Annals ol‘ Oncology, 2013, pages 31 -8, Volume
`24(1).
`Efstathiou, Eleni, et al. Effects ofAbiraterone Acetate on Androgen Signaling in Castrate-
`Resistant Prostate Cancer in Bone, American Society of Clinical Oncology, Joumal of
`Clinical Oncolog, 2011, pages 1-8.
`Huggins, Charles, et al. Studies on Prostatic Cancer]. The liiffect ol‘Castration, ol‘Estrogen
`and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate,
`Cancer Research, 1941, pages 293-297, Volume 1.
`Mostaghel, EA. et al. Molecular Pathways: Targeting resistance in the androgen receptor for
`therapeutic benefit, Clin Cancer Res, 2013 Dec 4. Ep_uQ_aheaCl of priflg._
`Nishimura, Kazuo, et al. Potential Mechanism for the Effects ol’Dexarnethasone on Growth
`of Androgen-Indeperident Prostate Cancer, Journal of the National Cancer Institute, 2001,
`
`__
`
`l_
`
`_l_
`
`Tgages 1739-1746, Volume 93.
`
`+
`
`Oudar, Stephane, et al. Actualite dans le cancer de la prostate, Synthese, Bull Cancer 2005;
`92 (10), pgs. 865-873 (relevance in English abstract)
`Petrylak, et al. Docetaxel and Estramiistine Compared with Mitoxantrone and Prednisone
`for Advanced Refractory Prostate Canccr, The New [England Journal of Medicine, 2004,
`pages 1513-20, Volume 351.
`Ryan, et al., Aberaterone Acetate in Metastatic Prostate C anccr Without Previous
`___Chcmothcrapy; The New England Journal ol‘ Medicine, 2013, 368138-148.
`Sartor, et al, I\i)i3'til-'r)l”()Tlt‘I Prolongs Sinvivz-:1 in Metastzslii: l‘i'osi-alt: ifzzticr-i’,
`l‘~§iittirc l{evicws
`Clinical ()ncole,gy, ZOE 1, pages 515-16, Volume 8,
`Tannock, IF, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced
`prostate cancer, The New F/ngland Journal of Medicine, 2004, pages 1502-1512, Volume
`351(15).
`
`_4
`
`
`
`,
`,
`Examiner
`
`/Sari Min Hail
`‘EXAMINER: lnitial it reference considered. whether or not citation is in colomiance with MPEP 609. Draw 1
`next nnmnuinii-.mnn tn appllr;-ml
`1 Unique citation designation nuniber. 2 Applicant is to place a check mark here i1Eng|isti language Translation is :itt:ir;tied
`Burden Hoiir Stateincrit This lurm is estiiriated to take 2 0 hours to mniplete. ‘fime will vary depending upon the needs of the individuzil case Any comments on the anouii ol time you are requred to
`complete this term should be sent to the Chief lnlormation Oflioer, U 8 Patent and Trademark Olfice. Washington, DC 20231.
`DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO‘ Commissioner for Patents, P O Box 1450, Alexandria, VA 22313-1450
`
`,
`1
`~;ir
`Dt
`O:/139/2014
`ine through citation it not in mntoririance and not considered include copy oi this lorin with
`
`
`
`ALL REFERENCES CC>l\lSlDERED EXCEPT WHERE UNED THROUGH.
`
`/S.l-ii’
`
`

`

`Application/Control No.
`
`Index Of C/aims
`
`13034340
`
`Applicant(s)/Patent Under
`Reexamination
`AUERBACH ET AL.
`
`
`
`
`
`
`
`
`
`SAN-MING HUI
`
`1629
`
`
`Rejected
` Allowed
`
`-
`U
`[ —:-
`
`Cancelled
`Restricted
`
`IFN 1 Non-Elected
`“
`I
`I
`Interference Objected
`
` ‘
`C] Claims renumbered in the same order as presented by applicant
`
`E] CPA
`
`I] T.D.
`
`CLAIM
`
`Final
`
`Original
`
`1
`
`11/21/2011 I01/27/2012 09/05/2012 02/25/2013
`
`1___..
`
`2
`L_—
`1 J 3
`
`E] R.1.47
`
`-1
`
`DATE
`
`06/28/2013 10/21/2013 01/29/2014
`
`_J
`
`._
`
`J T I
`
`’‘‘‘' —i"‘
`
`— ——i
`
`1 I
`
`"1.
`
`_.:..._._,_
`
`367
`U S Patent and ‘ rademark Office
`
`i
`
`Part of Paper No.
`
`1
`
`: 20140128
`
`

`

`Index 01' Claims
`'
`I
`
`
`
`
`
`
`Rejected
`Allowed
`
`= H
`
`-
`-:-
`
`Application/Control No.
`
`Applicant(s)/Patent Under
`Reexamination
`
`13034340
`Examiner
`
`SAN—MlNG HUI
`
`AUERBACH ET AL.
`Art Unit
`
`1629
`
`‘J
`
`Cancelled
`Restricted
`
`I
`’
`
`N
`I
`
`Non-Elected
`Interference
`
`A
`O
`
`Appeal
`Objected
`
`E] Claims renumbered in the sameorder as presented by applicant
`DATE
`F‘
`CLAIM —l
`Final
`Original 117/21/2011 01/27/201259‘/o5/2012[o2/25/20133528/253‘10/21/2013 01/29/2014
`37
`w’
`J
`/
`=
`=
`7
`—=
`
`38 ‘l
`_r
`F 40
`fi_
`F 41
`I’
`42
`43
`I
`44
`45
`"’”—’”—“""7:? l—
`47
`43
`49
`r 50
`51
`52
`53
`54
`55
`55
`
`39
`
`T
`
`i
`
`L
`
`*‘
`L
`
`—_-J
`
`/
`
`r
`
`l
`
`l
`L
`
`‘-1
`L
`
`J
`»/ —'
`»/
`J
`-L‘
`w’
`J’
`r
`‘I’
`l
`J
`»/
`/
`l— «
`/
`w "L x
`3
`,3
`/
`/
`J
`J
`,
`,
`»/
`\/
`»/
`\/
`/
`./
`«
`«
`x
`«'
`x/
`/
`»/
`»/
`/
`\/‘
`
`x
`
`[
`
`J’
`
`l
`
`‘L I
`./
`\/'
`V
`V
`/
`w
`,
`"I
`l__ ./
`V
`\/
`w/
`I
`« T
`/
`»/
`x/'
`¢‘
`
`_F
`
`T
`
`r
`
`T"
`3
`
`‘l
`
`k
`
`[3 CPA
`
`E] T.D.
`
`_—_ L =
`___
`I
`=
`=
`=
`‘
`=
`_-_—
`-_-
`L
`=
`=
`=
`=
`= j =
`=
`=
`=
`=
`=
`=
`_—_
`,—;
`=
`=
`=
`=
`=
`3
`=
`=
`=
`=
`_._
`=
`
`._.
`
`=
`
`L
`
`L
`r
`
`4
`
`F
`
`A
`
`I
`
`1
`L
`
`L
`
`B‘.
`
`=
`
`“F
`
`l
`
`.1
`
`-_—
`=
`=
`=
`J‘
`—_-
`=
`= L
`3
`=
`___
`=
`:
`=
`=
`=
`=
`:
`= T
`
`C] R.1.47
`
`4
`
`L
`J
`j
`
`{_-
`r—
`
`wi-
`‘_-
`
`J
`
`k
`
`‘I
`
`J
`‘J
`
`J
`
`1-1
`
`ll
`
`E
`
`US.PatentandTrademarkOffice
`
`PartofPaperNo.20140128
`
`

`

`AppIicant(s)/Patent Under
`Reexamination
`
`AUERBACH ET AL.
`
`Application/Control No.
`
`Search NOTES
`
`13034340
`
`
`
`
`
`
`
`Examiner
`
`SAN—M|NG HUI
`
`CPC- SEARCHED
`
`Symboi
`
`Art Unit
`
`1628
`
`I
`
`Date
`
`Examiner‘;
`
`Examiner
`
`Examiner
`
`SH
`SH
`SH
`SH
`
`SH
`
`SH
`
`I
`
`I
`
`CPC COMBINATION SETS — SEARCHED
`
`L
`
`Symbol
`
`I
`
`Date
`
`Class
`
`F
`
`514
`I514
`__514
`514
`
`W4
`
`514
`
`I
`
`1 170,182
`170, 182
`170,182
`170, 182
`
`fl 170, 182
`
`170,182
`
`US CLASSIFICATION SEARCHED
`
`Subclass
`
`I
`
`Date
`
`1/27/11
`9/5/12
`2/25/13
`8/28/13
`
`10/21/13
`
`1/29/14
`
`
`
`SH
`SH
`SH
`
`SH
`SH
`
`Examiner
`
`SEARCH NOTES
`
`Search Notes
`EAST Search and inventor search in PALM
`EAST search and inventor search in PALM
`LEAST search and inventor search in PALM
`EAST search and inventor search in PALM
`EAST search and inventor search in PALM
`LEAST search and inventor search in PALM
`
`Date
`1/27/11
`9/5/12
`2/25/18
`6/28/2013
`10/21/13
`1/29/14
`
`CPC Symbol
`
`US Class/
`L514
`
`514
`
`INTERFERENCE SEARCH
`
`US Subclass / CPC Group
`
`170,182
`
`170,182
`
`I
`fl
`
`Date
`6/28/13
`
`I 10/21/18
`
`Examiner
`SH
`
`SH
`
`US. F’a1en1 and Trademark Office
`
`Part of Paper No.
`
`. 20140128
`
`

`

`
`
`US Class/
`CPC Symbol
`514
`
`170,182
`
`INTERFERENCE SEARCH
`US Subclass / CPC Group
`
`Date
`1/29/14
`
`Examiner
`SH
`
`I
`I
`J
`
`U S. Paiem and Trademark Office
`
`Pad of Paper No . 20140128
`
`

`

`Application/Control No.
`Issue Classification 13034340
`
`App|lcant(s)/Patent Under Reexamination
`AUERBACH ET AL.
`
`Hlllllllllllllillllll/llfllilllfl
`
`llllilll II!
`
`:::'?;T:;
`
`(Assistant Examiner)
`/SAN-MING HU|/
`
`Primary Examiner./\r1 UM1621
`
`Total Claims Allowed:
`
`20
`
`01/29/2014
`
`0 G. Print Ciaim(s)
`
`O.G. Prim Figure (Primary Examiner)
`
`1(Date) 1
`US. Patent and Trademark Office
`Pan of Paper No. 20140128
`
`
`
`
`
`

`

`
`
`
`
`
`
`Application/Control No. Applicant(s)/Patent Under Reexamination
`
`AUERBACH ET AL.
`Issue Classification
` 13034340
`lllllllltlllllillllllllllfllllllllililllllilililll
`Examiner
` SAN~M|NG HUI
`
`US ORIGINAL CLASSIFICATION
`INTERNATIONAL CLASSIFICATION
` SUBCLASS NON-0'-WED
`514
`170
`1
`K
`31 / 56 (2006 O)
`
`CROSS REFERENCE(S)
`
`CLASS
`514
`
`SUBCLASS (ONE SUBCLASS PER BLOCK)
`
`r
`
`I80
`
`(Assistam Examiner)
`/SAN-MING HU|/
`
`Total Claims Allowed:
`
`20
`
`
`
`Primary Examiner./M Unit 1621
`01/29/2014
`O G. Prim C|aim(s)
`O,G. Prim Figure
`1 US. Paient and Trademark Office(Primary Examiner) (Dene) 1
`Pan of Paper No. 20140128
`
`
`
`
`
`
`
`

`

`Application/Control No.
`Issue Classification 13034340
`
`Applicant(s)/Patent Under Reexamination
`
`AUERBACH ET AL.
`
`Hll